Collecting saliva samples to study MuSK myasthenia gravis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The MuSK Myasthenia 1000 study aims to gather saliva samples from 1000 individuals diagnosed with MuSK myasthenia gravis to explore genetic variations linked to this condition. By analyzing these samples, researchers hope to enhance understanding of the disease's causes and identify potential biomarkers for targeted therapies. The study will utilize a genome-wide association study (GWAS) approach, conducted by Dr. Bryan Traynor at the NIH, to uncover genetic factors that contribute to MuSK myasthenia gravis. This observational study is crucial for paving the way toward new treatment options for patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Lab test confirming diagnosis of MuSK myasthenia gravis
* Willingness to provide saliva sample via mail or in person

Exclusion Criteria:

* Inability to provide informed consent
* Unwillingness to provide lab results of elevated muscle specific kinase antibody
* Unwillingness to provide saliva sample

Where it's running

• George Washington University
  Washington D.C., District of Columbia, United States Recruiting

Study contacts

• Study coordinator: Gulsen Oztosun, MD
• Email: musk1000@mfa.gwu.edu
• Phone: 202-677-6109

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MG patient registry to track long-term experiences and treatment patterns

  This registry collects information from adults with myasthenia gravis to see how symptoms and quality of life change over time and how treatments relate to those changes.

  Recruiting Autoimmune Neurology Alliance · Framingham, Massachusetts · NCT07761026

• Ublituximab maintenance after efgartigimod response in myasthenia gravis

  This study tests whether giving ublituximab as maintenance after a positive response to efgartigimod helps adults with myasthenia gravis.

  Recruiting at 7 sites Phase 2 TG Therapeutics, Inc. · Colorado Springs, Colorado and 6 other locations · NCT07673744

• Pregnant Women with Neuroimmune Diseases: A long-term follow-up study

  This study follows women with neuroimmune diseases and healthy controls through pregnancy and up to ten years to see how pregnancy affects disease activity and outcomes for both mother and baby.

  Recruiting Third Affiliated Hospital, Sun Yat-Sen University · Guangzhou, Guangdong · NCT07653984

• Early ravulizumab for adults with myasthenic crisis in the ICU

  This project will test whether giving ravulizumab early to adults with AChR-positive generalized myasthenia gravis who are in the ICU for a myasthenic crisis helps speed recovery.

  Recruiting at 5 sites Centre Hospitalier Universitaire de Nice · Nice, Alpes-maritimes and 7 other locations · NCT07411963

• KITE-363 treatment for relapsed or refractory autoimmune neurologic diseases

  This study will test whether KITE-363 is safe and can help people with relapsed or treatment-resistant autoimmune neurologic diseases such as MS, CIDP, and myasthenia gravis.

  Recruiting at 10 sites Phase 1 Gilead Sciences · Newport Beach, California and 9 other locations · NCT07304154

• ADAPT Forward master protocol testing multiple regimens for generalized myasthenia gravis

  This platform tests several drug regimens, including efgartigimod IV and empasiprubart IV, in adults with generalized myasthenia gravis to find safer and more effective treatment combinations.

  Recruiting at 37 sites argenx · Carlsbad, California and 36 other locations · NCT07294170

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.